Abaloparatide

Abaloparatide is a manufactured 34-amino-acid peptide modeled on parathyroid hormone-related protein, or PTHrP. It binds the G-protein-coupled PTH1 receptor on bone-forming cells; it is not itself a receptor. Treatment is a daily subcutaneous injection. FDA approval dates to 2017; the associated product names include Tymlos and Eladynos.

Supporting references: parathyroid hormone-related protein (PTHrP); PTH1R, a G-protein-coupled receptor; Tymlos.

Bone remodeling continuously removes old bone and creates new bone. Abaloparatide promotes formation more rapidly than resorption, creating an anabolic window. PTH1R signaling also affects calcium and phosphate balance. The resulting change in bone mineral density concerns the mineral content of bone and helps explain the fracture-reduction rationale.

Supporting references: torn down (resorption) and rebuilt (formation); bone mineral density.

ACTIVE reported an 86% relative reduction in new vertebral fractures and 43% in nonvertebral fractures versus placebo. Bone-density differences were apparent by six months. The described abaloparatide course is limited to two years.

Supporting references: ACTIVE.

Abaloparatide is used for postmenopausal osteoporosis and for men with osteoporosis at high fracture risk, including people who did not respond to or tolerate other treatment. Falling estrogen after menopause removes a brake on bone resorption, particularly affecting spine and hip. This therapy actively builds bone rather than only slowing breakdown. Prior fractures, very low density or several risk factors can support its specialist use.

Supporting references: men with osteoporosis.

Reported effects include dizziness, nausea, headache, a fast heartbeat, fatigue, vertigo, injection-site redness, swelling or bruising, joint or bone pain, abdominal bloating or pain and diarrhea. More serious concerns are hypercalcemia and hypercalciuria, the latter potentially contributing to kidney stones.

Prescribing precautions describe avoidance in people with higher baseline bone-cancer risk, including Paget disease, prior skeletal cancer or radiation to the skeleton, or unexplained alkaline-phosphatase elevation. Existing high blood calcium and a tendency to calcium-containing kidney stones also require attention.

Teriparatide, a PTH fragment, was first approved in 2002, 15 years before abaloparatide. Both activate PTH1R and are daily bone-anabolic injections; the comparison discusses a two-year duration for both; teriparatide’s label history is addressed separately. Abaloparatide instead models PTHrP. ACTIVE included teriparatide as an active-control arm rather than providing a standalone head-to-head superiority design.

New spine fractures were reduced 86% with abaloparatide and 80% with teriparatide versus placebo, without one established as better for that outcome. Nonvertebral fracture reduction was statistically significant at 43% for abaloparatide, while the 28% teriparatide reduction was not significant in that trial. Major osteoporotic fractures were 55% lower with abaloparatide than teriparatide. Spine-density gains were similar, while hip and femoral-neck gains favored abaloparatide. Hypercalcemia was reported in 3.4% versus 6.4%, respectively.

Supporting references: first-in-class.